Increasing antipsychotic dose for non response in schizophrenia.

The Cochrane Database of Systematic Reviews
Myrto T SamaraStefan Leucht

Abstract

Many people with schizophrenia do not reach a satisfactory clinical response with a standard dose of an initially prescribed antipsychotic drug. In such cases, clinicians face the dilemma of increasing the antipsychotic dose in order to enhance antipsychotic efficacy. To examine the efficacy of increasing antipsychotic dose compared to keeping the same dose in the treatment of people with schizophrenia who have not responded (as defined in the individual studies) to an initial antipsychotic drug trial. We also examine the adverse effects associated with such a procedure. We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials. All relevant randomised controlled trials (RCTs), reporting useable data, comparing increasing the antipsychotic dose rather than maintaining the original dose for people with schizophrenia who do not respond to their initial antipsychotic treatment. At least two review authors independently extracted data . We analysed dichotomous data using relative risks (RR) and the 95% confidence intervals (CI). We analysed continuous data using mean differences (MD) and their 95% CI. We assessed ...Continue Reading

References

May 1, 1978·Acta Psychiatrica Scandinavica·S J DenckerU Malm
Aug 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·R G McCreadieA Jorgensen
Nov 1, 1992·Journal of General Internal Medicine·G W DivineL M Frazier
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher
Jan 1, 1987·International Clinical Psychopharmacology·C C HuangL Hollister
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
May 1, 1981·The American Journal of Psychiatry·M H BrancheyM A Richardson
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen, S Olsen
Mar 10, 1994·The New England Journal of Medicine·W T Carpenter, R W Buchanan
Jan 17, 1997·Schizophrenia Research·J HirschowitzC Curtis
Sep 26, 1997·BMJ : British Medical Journal·J M Bland, S M Kerry
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jan 20, 1998·The American Journal of Psychiatry·W CoryellP J Perry
Feb 20, 1998·BMJ : British Medical Journal·G Davey Smith, M Egger
Dec 1, 1999·Biological Psychiatry·J M Kane
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M MarshallM Fenton
Sep 6, 2000·Pharmacology·D W Nebert, M Z Dieter
Mar 27, 2002·International Journal of Epidemiology·Diana R ElbourneAndy Vail
Sep 27, 2002·Statistics in Medicine·Allan Donner, Neil Klar
Aug 16, 2003·Journal of Clinical Psychopharmacology·Robert W BakerAngela L Hill
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
May 11, 2004·Social Psychiatry and Psychiatric Epidemiology·Steven Marwaha, Sonia Johnson
Jun 23, 2004·Journal of Clinical Psychopharmacology·John M Davis, Nancy Chen
Jun 30, 2004·CNS Drugs·Bruce J KinonPeter F Buckley
Mar 9, 2005·Archives of General Psychiatry·Brian A PalmerJohn Michael Bostwick
Jun 29, 2005·Schizophrenia Research·Stefan LeuchtRolf R Engel
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 4, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Stefan LeuchtRolf Engel
Dec 20, 2005·Journal of Clinical Epidemiology·Toshi A FurukawaNorio Watanabe
Aug 15, 2006·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Oct 13, 2006·European Archives of Psychiatry and Clinical Neuroscience·Markus JägerHans-Jürgen Möller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Cochrane Database of Systematic Reviews
Michael Lacey, Mahesh B Jayaram
The Cochrane Database of Systematic Reviews
Javier Ortiz-OrendainClive E Adams
The Cochrane Database of Systematic Reviews
Karla Soares-WeiserHanna Bergman
The Cochrane Database of Systematic Reviews
Naemeh NikvarzNavid Khalili
© 2022 Meta ULC. All rights reserved